Germany Just Made It Harder to Sell Drugs in Europe's Biggest Market

Six months to charge premium prices instead of twelve. For a blockbuster drug generating hundreds of millions in that first year, the math is brutal.

But the most eyebrow-raising provision might be the new pilot program for tender-style contracts on patented drugs. Tendering (competitive bidding) has traditionally been reserved for generics, the commodity end of the pharma world. Applying it to patent-protected medicines is a philosophical shift: treating branded, innovative drugs more like interchangeable products. The pilot runs through 2030.

Patients aren't escaping unscathed either. Minimum prescription co-payments jump from €5 to €7.50, and the maximum rises from €10 to €15.

Pharma's Reaction: "High-Risk Hub"

The industry response has been loud and pointed.

Han Steutel, president of vfa (the association of research-based pharma companies in Germany), warned that tying rebates to insurer budgets rather than therapeutic value destroys planning certainty. He pointed to a previous rebate hike from 7% to 12% in 2023, which he said cost Germany around €2 billion in lost investment. His argument: if you decouple pricing from the benefits a medicine actually delivers, you're punishing innovation.

Dorothee Brakmann of Pharma Deutschland went further. She said the dynamic rebate would turn Germany from a "high-tech hub" into a "high-risk hub," warning that unpredictable, budget-driven pricing directly hurts launch decisions, investment planning, and drug supply security.

The complaints aren't purely self-serving. Germany has historically offered something rare in European pharma: fast, broad patient access. That generous access has made Germany a magnet for drug launches. If profit margins shrink enough, companies might delay launches or skip the market entirely, which ultimately hurts patients.

Not All Bad News

To be fair, the government threw pharma a few bones. The law repeals the controversial combination therapy discount (a mandatory 20% markdown for certain drug combos) and eliminates the so-called "pricing guardrails" for new active substances. These were long-standing industry demands. The government also softened the dynamic rebate's design before the final vote.

But industry groups see these concessions as modest compared to the overall tightening. One step forward, three steps back.

Why the Rest of Europe Should Be Watching

Germany doesn't exist in a pricing vacuum. Many European countries use external reference pricing, where they set their own drug prices based on what other countries (including Germany) pay. When German prices drop, other countries can use those lower numbers to justify cutting their own reimbursement rates.

This creates a domino effect. A pharma company accepts lower net prices in Germany, and suddenly France, Spain, and Italy are pointing to those numbers in their own negotiations. It's why some drugmakers have historically been cautious about making deep concessions in large reference markets.

The dynamic rebate adds a new wrinkle. If manufacturers can't predict what their German net price will be from year to year, planning a coherent pan-European pricing strategy becomes significantly harder. Some analysts expect companies to respond by being more conservative with initial list prices, which would ripple through reference-pricing baskets across the continent.

The Bigger Picture

Germany is trying to close a significant funding gap in its statutory health insurance system. Drug spending grew about 6% in the prior year, and the government decided pharma needed to contribute its share of the pain. The reform also includes a future sugar tax (starting 2028), shifts insurance costs for the unemployed to the federal budget (about €12 billion annually), and trims other benefits.

The philosophical tension is real: Germany wants to be both a cost-conscious payer and an innovation-friendly pharma hub. Its recent Medical Research Act tried to sweeten the deal by offering faster clinical trial approvals and more flexible pricing for companies that anchor a relevant part of their global trial enrollment at German sites. Total financing for German biotech jumped 78% in 2024 to €1.9 billion, suggesting investors still see opportunity.

But there's a limit to how many times you can squeeze margins before companies start moving their R&D euros somewhere else. The industry spent €9.9 billion on R&D in Germany in 2023, making it the most research-intensive sector in the country. That's a lot of investment to put at risk.

The Bundestag has placed its bet: tighter pricing now, with targeted carrots for companies willing to anchor research in Germany. Whether pharma stays at the table or starts looking for friendlier markets will determine if this reform was smart fiscal policy or a strategic own goal.

Bayer Just Sold a Piece of Its Birth Control Empire (But Kept the Keys)

Bayer just pulled €3 billion from Apollo without giving up control of its blockbuster IUD franchise. It's a clever financial move, but the real story is why the German pharma giant needed the cash so badly in the first place.